Crystalline Dapagliflozin Hydrate

Patent No. EP2785702 (titled "Crystalline Dapagliflozin Hydrate") was filed by Sandoz on Nov 28, 2012. The application was issued on Jan 22, 2020.

Patent Summary

Crystalline dapagliflozin hydrate that has improved physical and/or biological characteristics which may assist in the manufacture or formulation of the active compound, to the purity levels and uniformity required for regulatory approval. The crystalline form comprises two encapsulated polyols, each containing one or more methanol, a solvent, or a mixture of solvents.

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UK TRADING MYLANOct 22, 2020GILL JENNINGS & EVERY

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2785702

SANDOZ
Application Number
EP12791764A
Filing Date
Nov 28, 2012
Status
Opposition Rejected
Apr 27, 2024
Publication Date
Jan 22, 2020